Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has initiated a preclinical…
